Chenyang Shi

Directeur/Membre du Conseil chez GENSCRIPT BIOTECH CORPORATION

56 ans

Consumer Services

Commercial Services

Health Technology

Postes actifs de Chenyang Shi

Sociétés	Poste	Début	Fin
GENSCRIPT BIOTECH CORPORATION	Directeur/Membre du Conseil	12/04/2024	-
GENSCRIPT BIOTECH CORPORATION	Independent Dir/Board Member	12/04/2024	-

Sociétés	Poste	Début	Fin
NuProbe USA, Inc. NuProbe USA, Inc. Miscellaneous Commercial ServicesCommercial Services NuProbe USA, Inc. engages in the development of ultra-sensitive and multiplexed platform with reagents for non-invasive nucleic acid profiling and diagnostics. The firm offers VarTrace EGFR Assay, VarTrace BFAR Assay, and VarTrace AML multi-gene panel. The company was founded by Peng Yin, David Yu Zhang, and Victor Chenyang Shi in 2016 and is headquartered in Cambridge, MA.	Directeur/Membre du Conseil	01/01/2016	-
	Directeur Général	01/01/2016	-
	Fondateur	01/01/2016	-
	President	01/01/2016	-

Rochester Christian University	Doctorate Degree
University of Science & Technology of China	Undergraduate Degree

Internationale

Etats-Unis	3
Chine	3

Opérationnelle

Sectorielle

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	1
GENSCRIPT BIOTECH CORPORATION	Health Technology

Entreprise privées	1
NuProbe USA, Inc. NuProbe USA, Inc. Miscellaneous Commercial ServicesCommercial Services NuProbe USA, Inc. engages in the development of ultra-sensitive and multiplexed platform with reagents for non-invasive nucleic acid profiling and diagnostics. The firm offers VarTrace EGFR Assay, VarTrace BFAR Assay, and VarTrace AML multi-gene panel. The company was founded by Peng Yin, David Yu Zhang, and Victor Chenyang Shi in 2016 and is headquartered in Cambridge, MA.	Commercial Services

Entreprise privées

Commercial Services